PBAC passes its first gene therapy

By Megan Brodie 3 years ago | In Cell and gene therapies, Regulatory
  • 3 years ago

18 October 2021 The PBAC has recommended Novartis’ gene therapy ZOLGENSMA (onasemnogene abeparvovec) for listing…

This is subscriber-only content. Please login to continue reading.